Advisornet Financial’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$542 Hold
1
– – ﹤0.01% 2091
2026
Q1
$593 Hold
1
– – ﹤0.01% 2077
2025
Q4
$487 Sell
1
-1
-50% -$466 ﹤0.01% 2095
2025
Q3
$838 Buy
+2
New +$673 ﹤0.01% 1991
2025
Q2
– Sell
-1
Closed -$308 – 2374
2025
Q1
$308 Hold
1
– – ﹤0.01% 2038
2024
Q4
$353 Buy
+1
New +$368 ﹤0.01% 1828
2024
Q1
– Sell
-14
Closed -$3.08K – 2504
2023
Q4
$3.08K Sell
14
-1
-7% -$230 ﹤0.01% 1605
2023
Q3
$3.39K Buy
15
+1
+7% +$230 ﹤0.01% 1517
2023
Q2
$3.09K Buy
+14
New +$3.1K ﹤0.01% 1621
2023
Q1
– Sell
-13
Closed -$3.62K – 2491
2022
Q4
$3.62K Buy
+13
New +$3.28K ﹤0.01% 1543

Other funds holding UTHR

Advisornet Financial's UTHR Position: Q2 2026 in Review

Advisornet Financial held its United Therapeutics (UTHR) position steady in Q2 2026 at 1 share worth $542. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Advisornet Financial first reported a position in UTHR in Q4 2022 and has held it in 10 quarters since. The position peaked at $3.62K in Q4 2022. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Advisornet Financial held 1 share of United Therapeutics worth $542 as of Q2 2026.
  • Advisornet Financial left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #2091 holding.
  • Advisornet Financial first reported a position in United Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Advisornet Financial's United Therapeutics position peaked at $3.62K in Q4 2022.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.